stockportfolio.pro
GE HealthCare Technologies Inc. (GEHC)
Healthcare · Medical Devices · NasdaqGS
GE HealthCare Technologies Inc. revenue & earnings — last 5 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.59B | $18.34B | $19.55B | $19.67B | $20.63B |
| Gross profit | $7.17B | $7.18B | $7.92B | $8.21B | $8.25B |
| Net income | $2.25B | $1.92B | $1.57B | $1.99B | $2.08B |
| Net margin | 12.8% | 10.4% | 8.0% | 10.1% | 10.1% |
Source: GE HealthCare Technologies Inc. SEC filings (10-K).
What growth is priced into GEHC stock?
At today's market cap of $30.03B, GE HealthCare Technologies Inc. is priced for free-cash-flow growth of about 7.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.50B from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 5 years of GE HealthCare Technologies Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GEHC in your portfolio →
GE HealthCare Technologies Inc. financial history by metric
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
GE HealthCare Technologies Inc. — frequently asked questions
What is GE HealthCare Technologies Inc.'s revenue?
GE HealthCare Technologies Inc. (GEHC) reported revenue of $20.63B for fiscal year 2025, up 4.8% from the prior year, according to its SEC filings.
Is GE HealthCare Technologies Inc. profitable?
Yes. GEHC earned net income of $2.08B in fiscal 2025, a net margin of 10.1%.
What is GEHC's P/E ratio?
GE HealthCare Technologies Inc. trades at a price-to-earnings ratio of about 15.8 based on the latest data in our nightly-refreshed cache.
How fast is GE HealthCare Technologies Inc. growing?
GEHC's revenue grew at roughly 4.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does GE HealthCare Technologies Inc. have?
As of fiscal year 2025, GEHC carried roughly $10.51B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is GE HealthCare Technologies Inc.'s gross margin?
GEHC's gross margin was 40.0% in fiscal 2025 — gross profit of $8.25B on revenue of $20.63B.
What is GE HealthCare Technologies Inc.'s market cap?
GE HealthCare Technologies Inc. (GEHC) has a market capitalization of about $30.03B, based on the latest data in our nightly-refreshed cache.
When does GE HealthCare Technologies Inc.'s fiscal year end?
GEHC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into GEHC stock?
At today's market cap of $30.03B, GE HealthCare Technologies Inc. is priced for free-cash-flow growth of about 7.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.50B from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from GE HealthCare Technologies Inc.'s official SEC filings (10-K and 10-Q), covering 5 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.